Analysis of common adverse reactions of Teritusumab/Telivac

Teritusumab (Teclistamab-cqyv), as an immunotherapy drug, has shown significant efficacy in the treatment of multiple myeloma (MM) and other hematological diseases. However, like all immunotherapies, teritusumab may also cause some adverse reactions, and patients need to be aware of and promptly monitor possible side effects during treatment. The following are common adverse reactions of teritusumab:

1. Fever is one of the most common adverse reactions, which usually appears at the beginning of treatment, and in most cases, symptoms will alleviate as treatment continues.

2. Cytokine release syndrome (CRS) is a typical side effect of immunotherapy. It usually presents with symptoms such as fever, hypotension, and shortness of breath. Although most cases are self-limiting, severe cases require emergency treatment.

3. Musculoskeletal pain is also one of the common adverse reactions. Patients may feel pain in joints and muscles, especially in the early stages of treatment. The pain is usually temporary but can be relieved with painkillers.

4. Injection site reactions, such as redness, swelling, pain, and itching, are also common side effects. Although these symptoms are generally mild, they may affect the patient's treatment experience. Fatigue, upper respiratory tract infections, nausea, headache, pneumonia, and diarrhea are also some common side effects. Fatigue can significantly affect a patient's daily activities, especially during treatment. Pneumonia and upper respiratory tract infections are more common because the immune system is affected.

In conclusion, although teritusumab has shown significant therapeutic effects, management of adverse effects is also very important. Patients should maintain communication with their doctors and promptly report any discomfort to ensure smooth progress of treatment.

Keyword tags: teritusumab,Teclistamab, adverse reactions, fever, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, infection, pneumonia

Reference materials:https://www.drugs.com/tecvayli.html